Cargando…
A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
The pentameric serum IgMs are critical to immune defense and surveillance through cytotoxicity against microbes and nascent cancer cells. Ficolins, a group of oligomeric lectins with an overall structure similar to C1q and mannose-binding lectin (MBL) participate in microbe infection and apoptotic c...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296296/ https://www.ncbi.nlm.nih.gov/pubmed/25592840 http://dx.doi.org/10.1038/srep07824 |
_version_ | 1782352952982241280 |
---|---|
author | Lei, Xiaoying Liu, Chaoxu Azadzoi, Kazem Li, Cuiling Lu, Fan Xiang, An Sun, Jianbin Guo, Yanhai Zhao, Qingchuan Yan, Zhen Yang, Jinghua |
author_facet | Lei, Xiaoying Liu, Chaoxu Azadzoi, Kazem Li, Cuiling Lu, Fan Xiang, An Sun, Jianbin Guo, Yanhai Zhao, Qingchuan Yan, Zhen Yang, Jinghua |
author_sort | Lei, Xiaoying |
collection | PubMed |
description | The pentameric serum IgMs are critical to immune defense and surveillance through cytotoxicity against microbes and nascent cancer cells. Ficolins, a group of oligomeric lectins with an overall structure similar to C1q and mannose-binding lectin (MBL) participate in microbe infection and apoptotic cell clearance by activating the complement lectin pathway or a primitive opsonophagocytosis. It remains unknown whether serum IgMs interplay with ficolins in cancer immunosurveillance. Here we report a natural cancer killing of different types of cancer cells by sera from a healthy human population mediated by a novel IgM–H-ficolin complement activation pathway. We demonstrate for the first time that H-ficolin bound to a subset of IgMs in positive human sera and IgM–H-ficolin deposited on cancer cells to activate complement attack in cancer cells. Our data suggest that the IgM–H-ficolin -mediated complement activation pathway may be another defensive strategy for human cancer immunosurveillance. |
format | Online Article Text |
id | pubmed-4296296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-42962962015-01-16 A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro Lei, Xiaoying Liu, Chaoxu Azadzoi, Kazem Li, Cuiling Lu, Fan Xiang, An Sun, Jianbin Guo, Yanhai Zhao, Qingchuan Yan, Zhen Yang, Jinghua Sci Rep Article The pentameric serum IgMs are critical to immune defense and surveillance through cytotoxicity against microbes and nascent cancer cells. Ficolins, a group of oligomeric lectins with an overall structure similar to C1q and mannose-binding lectin (MBL) participate in microbe infection and apoptotic cell clearance by activating the complement lectin pathway or a primitive opsonophagocytosis. It remains unknown whether serum IgMs interplay with ficolins in cancer immunosurveillance. Here we report a natural cancer killing of different types of cancer cells by sera from a healthy human population mediated by a novel IgM–H-ficolin complement activation pathway. We demonstrate for the first time that H-ficolin bound to a subset of IgMs in positive human sera and IgM–H-ficolin deposited on cancer cells to activate complement attack in cancer cells. Our data suggest that the IgM–H-ficolin -mediated complement activation pathway may be another defensive strategy for human cancer immunosurveillance. Nature Publishing Group 2015-01-16 /pmc/articles/PMC4296296/ /pubmed/25592840 http://dx.doi.org/10.1038/srep07824 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Article Lei, Xiaoying Liu, Chaoxu Azadzoi, Kazem Li, Cuiling Lu, Fan Xiang, An Sun, Jianbin Guo, Yanhai Zhao, Qingchuan Yan, Zhen Yang, Jinghua A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro |
title | A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro |
title_full | A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro |
title_fullStr | A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro |
title_full_unstemmed | A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro |
title_short | A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro |
title_sort | novel igm–h-ficolin complement pathway to attack allogenic cancer cells in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296296/ https://www.ncbi.nlm.nih.gov/pubmed/25592840 http://dx.doi.org/10.1038/srep07824 |
work_keys_str_mv | AT leixiaoying anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT liuchaoxu anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT azadzoikazem anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT licuiling anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT lufan anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT xiangan anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT sunjianbin anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT guoyanhai anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT zhaoqingchuan anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT yanzhen anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT yangjinghua anoveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT leixiaoying noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT liuchaoxu noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT azadzoikazem noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT licuiling noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT lufan noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT xiangan noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT sunjianbin noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT guoyanhai noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT zhaoqingchuan noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT yanzhen noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro AT yangjinghua noveligmhficolincomplementpathwaytoattackallogeniccancercellsinvitro |